Immunocore Holdings (IMCR) Receivables - Other (2019 - 2023)

Immunocore Holdings has reported Receivables - Other for 5 years, with the latest figure at $6.9 million in Q2 2023.

• Quarterly Receivables - Other changed N/A year-over-year to $6.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $6.9 million (changed N/A YoY) and the FY2022 annual result came in at $9.0 million, up 345.5% from the prior year.
• Receivables - Other declined to $6.9 million in Q2 2023 per IMCR's latest filing, from $9.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $9.0 million in Q4 2022 and troughed at $2.0 million in Q4 2021.
• A 5-year average of $5.4 million and a median of $5.8 million in 2019 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2020 and 2022: Receivables - Other plunged 51.77% in 2020, then jumped 354.71% in 2022.
• Over 5 years, Receivables - Other stood at $4.7 million in 2019, then slumped by 51.77% to $2.3 million in 2020, then slipped by 12.85% to $2.0 million in 2021, then surged by 354.71% to $9.0 million in 2022, then slipped by 23.27% to $6.9 million in 2023.
• According to Business Quant data, Receivables - Other over the past three periods registered $6.9 million, $9.0 million, and $7.3 million for Q2 2023, Q4 2022, and Q3 2022 respectively.